{"id":"xenical","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Oily spotting","drugRate":"","severity":"common","organSystem":""},{"effect":"Flatus with discharge","drugRate":"","severity":"common","organSystem":""},{"effect":"Fecal urgency","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatty/oily stool","drugRate":"","severity":"common","organSystem":""},{"effect":"Oily evacuation","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased defecation","drugRate":"","severity":"common","organSystem":""},{"effect":"Fecal incontinence","drugRate":"","severity":"common","organSystem":""},{"effect":"Gastrointestinal symptoms","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypoglycemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal distension","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Anorexia nervosa","Bulimia nervosa","Calcium Oxalate Renal Calculi","Drug-induced hepatitis","Hepatic failure","Hepatic necrosis","Liver function tests abnormal","Malabsorption States","Obstruction of bile duct","Primary hyperoxaluria","Vitamin deficiency"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Hepatic failure","drugRate":"","severity":"serious"},{"effect":"Hepatitis","drugRate":"","severity":"serious"},{"effect":"Increased transaminases","drugRate":"","severity":"serious"},{"effect":"Increased alkaline phosphatase","drugRate":"","severity":"serious"},{"effect":"Hypersensitivity reactions","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Urticaria","drugRate":"","severity":"serious"},{"effect":"Rash","drugRate":"","severity":"serious"},{"effect":"Pruritus","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL175247","moleculeType":"Small molecule","molecularWeight":"495.75"},"aliases":["Orlistat"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"6240792b-9224-2d10-e053-2a91aa0a2c3e","title":"XENICAL (ORLISTAT) CAPSULE [H2-PHARMA LLC]"},"ecosystem":[],"mechanism":{"target":"Abhydrolase domain-containing protein 16A, Endothelial lipase, Fatty acid synthase"},"_scrapedAt":"2026-03-28T00:16:19.816Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Obesity","diseaseId":"obesity","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07301437","phase":"PHASE4","title":"RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-05-01","conditions":"Overweight and Obese Adults","enrollment":120},{"nctId":"NCT01351753","phase":"PHASE2","title":"Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2011-03","conditions":"Obesity, Metabolic Syndrome X","enrollment":128},{"nctId":"NCT07437001","phase":"NA","title":"Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-01","conditions":"Postmenopausal Women","enrollment":60},{"nctId":"NCT05579249","phase":"PHASE4","title":"A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-19","conditions":"Obesity","enrollment":500},{"nctId":"NCT05503927","phase":"","title":"A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2023-01-02","conditions":"Pregnancy, Obesity, Overweight","enrollment":1139},{"nctId":"NCT07326839","phase":"NA","title":"Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT","status":"NOT_YET_RECRUITING","sponsor":"XueMei Guo","startDate":"2025-12-10","conditions":"Gout, Obesity","enrollment":120},{"nctId":"NCT06854614","phase":"PHASE4","title":"Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-03-01","conditions":"Obesity","enrollment":150},{"nctId":"NCT06877572","phase":"","title":"Weight Loss Management in Endometrial Cancer Survivors","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2025-03-25","conditions":"Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer","enrollment":50},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT06993428","phase":"PHASE2","title":"A Trial With EMP16 in Preparation for Late Phase Studies","status":"NOT_YET_RECRUITING","sponsor":"Empros Pharma AB","startDate":"2025-05-20","conditions":"Overweight or Obese, Obesity and Overweight","enrollment":39},{"nctId":"NCT05816343","phase":"PHASE2","title":"Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-01-26","conditions":"Type 1 Hyperlipoprotenemia","enrollment":28},{"nctId":"NCT05812183","phase":"PHASE4","title":"Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-07-09","conditions":"Dyspnea, Quality of Life","enrollment":""},{"nctId":"NCT06818955","phase":"PHASE2","title":"Orlistat Overcoming Third-generation EGFR-TKI Resistance","status":"NOT_YET_RECRUITING","sponsor":"Ping Peng","startDate":"2025-02-16","conditions":"Lung Adenocarcinoma, Osimertinib","enrollment":36},{"nctId":"NCT06625736","phase":"NA","title":"Anti-obesity Effects of Dandelion (Taraxacum Officinale L.)","status":"COMPLETED","sponsor":"October 6 University","startDate":"2024-01-05","conditions":"Obese Women, Perimenopause","enrollment":120},{"nctId":"NCT04531176","phase":"PHASE4","title":"EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-09-01","conditions":"Type 2 Diabetes, Obesity","enrollment":74},{"nctId":"NCT06501326","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2023-11-01","conditions":"Non-alcoholic Fatty Liver Disease, Obesity","enrollment":102},{"nctId":"NCT03582722","phase":"PHASE4","title":"Weight Loss Aid in an Exposed Population","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-09-14","conditions":"Polybrominated Biphenyl Poisoning","enrollment":100},{"nctId":"NCT06357273","phase":"","title":"The Effect of White Tea Consumption on Obesity","status":"COMPLETED","sponsor":"Recep Tayyip Erdogan University","startDate":"2023-07-01","conditions":"Obesity, Obesity; Endocrine, Obesity Adult Onset","enrollment":91},{"nctId":"NCT05934110","phase":"PHASE2","title":"Study Exploring the Supportive Effect of Acarbose in Weight Management","status":"UNKNOWN","sponsor":"Empros Pharma AB","startDate":"2023-04-18","conditions":"Overweight or Obesity","enrollment":320},{"nctId":"NCT05496075","phase":"PHASE4","title":"Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2022-08-26","conditions":"Uric Acid","enrollment":72},{"nctId":"NCT06013163","phase":"PHASE1","title":"A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers","status":"UNKNOWN","sponsor":"Empros Pharma AB","startDate":"2023-09-22","conditions":"Overweight or Obesity","enrollment":20},{"nctId":"NCT05760677","phase":"PHASE1","title":"Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-10-01","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, T2D","enrollment":142},{"nctId":"NCT02767531","phase":"PHASE2","title":"Orlistat for the Treatment of Type I Hyperlipoproteinemia","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2015-12","conditions":"Hyperlipoproteinemia Type I, Hypertriglyceridemia","enrollment":2},{"nctId":"NCT03799198","phase":"PHASE4","title":"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-07","conditions":"Obesity","enrollment":200},{"nctId":"NCT02041234","phase":"PHASE4","title":"Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2014-02","conditions":"Type II Diabetes in Subjects BMI 27 to 32","enrollment":40},{"nctId":"NCT04521751","phase":"PHASE1, PHASE2","title":"A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)","status":"COMPLETED","sponsor":"Empros Pharma AB","startDate":"2020-05-07","conditions":"Overweight or Obesity","enrollment":156},{"nctId":"NCT02432209","phase":"PHASE3","title":"Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-08","conditions":"Infertility, Female","enrollment":379},{"nctId":"NCT05076474","phase":"NA","title":"Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg","status":"COMPLETED","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2020-10-01","conditions":"Bioequivalence","enrollment":84},{"nctId":"NCT00292799","phase":"NA","title":"An RCT of Metformin Vs Orlistat in Obese Anovulatory Women","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2006-02","conditions":"Anovulation, Obesity","enrollment":36},{"nctId":"NCT01675154","phase":"PHASE2","title":"Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2015-11","conditions":"Type 1 Hyperlipoproteinemia","enrollment":5},{"nctId":"NCT03430284","phase":"PHASE4","title":"Multifactorial Intervention on Diabetes (MIDiab Study)","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2018-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":6300},{"nctId":"NCT01003483","phase":"PHASE2","title":"Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients","status":"COMPLETED","sponsor":"Yazd Research & Clinical Center for Infertility","startDate":"2008-12-01","conditions":"Obesity","enrollment":80},{"nctId":"NCT02541487","phase":"","title":"Fetal Effects of Pre-Pregnancy Lifestyle Interventions in Unexplained Infertility Patients","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2015-05-08","conditions":"Infertility","enrollment":22},{"nctId":"NCT03736551","phase":"NA","title":"Intermittent Low Energy Diet in CKD: MIX UP Feasibility Study","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2017-10-25","conditions":"Chronic Kidney Diseases, Obesity","enrollment":13},{"nctId":"NCT04417582","phase":"","title":"Life Style Modification Medical and Surgical Management in Patients With Obesity","status":"UNKNOWN","sponsor":"Marmara University","startDate":"2020-01-01","conditions":"Obesity, Weight Change, Body, Obesity; Endocrine","enrollment":1000},{"nctId":"NCT01755676","phase":"PHASE3","title":"Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults","status":"COMPLETED","sponsor":"EMS","startDate":"2016-09","conditions":"Obesity","enrollment":638},{"nctId":"NCT00829283","phase":"NA","title":"Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-11","conditions":"Obesity, Binge Eating","enrollment":191},{"nctId":"NCT00516919","phase":"PHASE4","title":"Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-08","conditions":"Obesity, Binge Eating","enrollment":79},{"nctId":"NCT03675191","phase":"NA","title":"Orlistat/Phentermine Versus Placebo/Phentermine","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2018-10-16","conditions":"Obesity, Overweight","enrollment":114},{"nctId":"NCT03884127","phase":"","title":"Ezetimibe and Orlistat Affect the Intestinal Flora of Hyperlipidemia.","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital of Xinjiang Medical University","startDate":"2019-04-01","conditions":"Hyperlipidemia","enrollment":58},{"nctId":"NCT00871845","phase":"NA","title":"Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients","status":"TERMINATED","sponsor":"Hossam Kandil","startDate":"2008-09","conditions":"Obesity, Insulin Resistance, Metabolic Syndrome","enrollment":36},{"nctId":"NCT02069197","phase":"PHASE2","title":"Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea","status":"UNKNOWN","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","startDate":"2014-01","conditions":"Obesity, Diabetes, Obstructive Sleep Apnea","enrollment":150},{"nctId":"NCT01128400","phase":"","title":"Fat Perception in Humans (09-0873)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-05","conditions":"Obesity","enrollment":40},{"nctId":"NCT01126970","phase":"PHASE2","title":"Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects","status":"COMPLETED","sponsor":"Shionogi","startDate":"2010-04","conditions":"Obesity","enrollment":486},{"nctId":"NCT01597531","phase":"PHASE4","title":"Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding","status":"TERMINATED","sponsor":"East Carolina University","startDate":"2012-06","conditions":"Type 2 Diabetes, Gastric Banding","enrollment":1},{"nctId":"NCT03383068","phase":"PHASE4","title":"Research of Intensive Metabolic Intervention Before Pregnancy in PCOS","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2018-01-01","conditions":"PCOS, Impaired Glucose Tolerance","enrollment":160},{"nctId":"NCT03336086","phase":"PHASE3","title":"Effect of Weight Reduction on Immunity","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2012-03-20","conditions":"Lymphocytes, Weight Loss, Viral Diseases","enrollment":29},{"nctId":"NCT00422058","phase":"PHASE2","title":"The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-01-10","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":564},{"nctId":"NCT01332448","phase":"","title":"Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02","conditions":"Obesity","enrollment":1},{"nctId":"NCT02372526","phase":"","title":"The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation","status":"UNKNOWN","sponsor":"Kirstine Nyvold Bojsen-Moeller","startDate":"2015-01","conditions":"Bariatric Surgery (Gastric Bypass), Overweight","enrollment":18},{"nctId":"NCT00704912","phase":"PHASE2","title":"Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-09","conditions":"Polycystic Ovary Syndrome","enrollment":217},{"nctId":"NCT00533481","phase":"PHASE2","title":"Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-02","conditions":"Obesity","enrollment":497},{"nctId":"NCT02141230","phase":"NA","title":"Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-12","conditions":"Weight Loss","enrollment":""},{"nctId":"NCT01053130","phase":"NA","title":"Weight Loss Interventions in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2010-01","conditions":"Chronic Kidney Disease, Obesity","enrollment":16},{"nctId":"NCT02706067","phase":"PHASE4","title":"Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-07","conditions":"Obesity","enrollment":50},{"nctId":"NCT00940628","phase":"PHASE3","title":"A Study of Xenical (Orlistat) in Overweight and Obese Adolescents","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Obesity","enrollment":60},{"nctId":"NCT00115063","phase":"PHASE4","title":"LOSS- Louisiana Obese Subjects Study","status":"TERMINATED","sponsor":"Pennington Biomedical Research Center","startDate":"2005-07","conditions":"Obesity","enrollment":390},{"nctId":"NCT01719419","phase":"NA","title":"The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects","status":"WITHDRAWN","sponsor":"Pennington Biomedical Research Center","startDate":"2012-03","conditions":"Overweight","enrollment":""},{"nctId":"NCT02503865","phase":"PHASE1, PHASE2","title":"Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome","status":"COMPLETED","sponsor":"Nazarbayev University","startDate":"2003-01","conditions":"Metabolic Syndrome","enrollment":351},{"nctId":"NCT02529631","phase":"NA","title":"RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity","status":"COMPLETED","sponsor":"Certmedica International GmbH","startDate":"2009-11","conditions":"Overweight, Obesity","enrollment":64},{"nctId":"NCT00794963","phase":"NA","title":"Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2008-11","conditions":"Metabolic Syndrome","enrollment":8},{"nctId":"NCT00541762","phase":"NA","title":"Regulation of Fat-stimulated Neurotensin Secretion in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2006-01","conditions":"Healthy","enrollment":34},{"nctId":"NCT01320228","phase":"NA","title":"Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2011-04","conditions":"Obesity","enrollment":69},{"nctId":"NCT00108524","phase":"NA","title":"A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2004-07","conditions":"Diabetes Mellitus, Obesity","enrollment":146},{"nctId":"NCT01035333","phase":"PHASE4","title":"A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.","status":"COMPLETED","sponsor":"Albany College of Pharmacy and Health Sciences","startDate":"2009-11","conditions":"Obesity","enrollment":19},{"nctId":"NCT00601354","phase":"NA","title":"Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-09","conditions":"Overweight, Eating Disorders","enrollment":17},{"nctId":"NCT00152360","phase":"PHASE4","title":"The Effect of Xenical on Weight and Risk Factors","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2005-06","conditions":"Obesity, Heart Diseases","enrollment":25},{"nctId":"NCT00752726","phase":"PHASE4","title":"Effect of Orlistat in Body Composition","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09","conditions":"Obesity, Overweight","enrollment":131},{"nctId":"NCT01797757","phase":"NA","title":"Comparison of MAG and Fish Oil Efficacy","status":"COMPLETED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2012-01","conditions":"Obesity","enrollment":46},{"nctId":"NCT01550926","phase":"PHASE1","title":"A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Overweight","enrollment":48},{"nctId":"NCT00001723","phase":"PHASE2","title":"Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases","status":"COMPLETED","sponsor":"Jack Yanovski","startDate":"1998-05","conditions":"Diabetes Mellitus, Hypertension, Metabolic Disease","enrollment":200},{"nctId":"NCT01387243","phase":"","title":"Survey on the Pharmacy Follow-up of Alli Purchasers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01","conditions":"Overweight","enrollment":80},{"nctId":"NCT00207311","phase":"PHASE4","title":"Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2005-08","conditions":"Fatty Liver, Hepatitis C","enrollment":30},{"nctId":"NCT01475019","phase":"PHASE4","title":"The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)","status":"UNKNOWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2004-01","conditions":"Obesity, Polycystic Ovaries Syndrome","enrollment":200},{"nctId":"NCT01414465","phase":"NA","title":"Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2009-10","conditions":"Overweight","enrollment":17},{"nctId":"NCT01047657","phase":"PHASE3","title":"Effects of Weight Loss in Obese Difficult-to-treat Asthmatics","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2009-11","conditions":"Asthma, Obesity, Weight Loss","enrollment":33},{"nctId":"NCT01170806","phase":"NA","title":"Study of Fat Malabsorption by Lipiblock Versus Xenical","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2009-10","conditions":"Obesity","enrollment":20},{"nctId":"NCT01184560","phase":"NA","title":"Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2010-02","conditions":"Obesity","enrollment":174},{"nctId":"NCT00212199","phase":"PHASE4","title":"Effectiveness of Brief Counseling for Weight Management","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2002-01","conditions":"1. Obesity","enrollment":246},{"nctId":"NCT00991926","phase":"","title":"Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat","status":"COMPLETED","sponsor":"Federico II University","startDate":"2006-12","conditions":"Obesity","enrollment":20},{"nctId":"NCT00160407","phase":"PHASE4","title":"Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2003-10","conditions":"Fatty Liver, Hepatitis","enrollment":50},{"nctId":"NCT00461799","phase":"NA","title":"Orlistat Treatment of Crigler-Najjar Disease","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2003-09","conditions":"Crigler-Najjar Syndrome","enrollment":16},{"nctId":"NCT00156897","phase":"PHASE2","title":"Efficacy and Safety of ATL-962 in Obese Diabetics","status":"COMPLETED","sponsor":"Alizyme","startDate":"2004-12","conditions":"Non-Insulin-Dependent Diabetes Mellitus, Obesity","enrollment":600}],"_emaApprovals":[],"_faersSignals":[{"count":177,"reaction":"DRUG INEFFECTIVE"},{"count":148,"reaction":"DIARRHOEA"},{"count":137,"reaction":"WEIGHT INCREASED"},{"count":124,"reaction":"NAUSEA"},{"count":116,"reaction":"ABDOMINAL PAIN"},{"count":106,"reaction":"DYSPNOEA"},{"count":103,"reaction":"HEADACHE"},{"count":95,"reaction":"FATIGUE"},{"count":92,"reaction":"PAIN"},{"count":87,"reaction":"ABDOMINAL PAIN UPPER"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20070105","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20020227","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20040709","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20020221","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20011219","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20011112","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20010625","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20010109","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20120120","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20000406","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20150807","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"19990831","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20041022","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20131016","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20130405","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20050902","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20020308","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20011219","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20010129","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20221117","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20000406","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20160812","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20100525","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20140430","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20090211","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20031212","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20130402","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"19990423","type":"ORIG","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"},{"date":"20101217","type":"SUPPL","sponsor":"CHEPLAPHARM","applicationNumber":"NDA020766"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":114,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Xenical","genericName":"Xenical","companyName":"Khoo Teck Puat Hospital","companyId":"khoo-teck-puat-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}